The two companies will enter a co-development partnership to deliver solutions from clinical to commercial-scale for single-use automated bioprocessing systems to enable accelerated product development.
A spokesperson for Pall told us, “The partnership is two-fold. It reflects Pall Biotech’s commitment to partnering for industry benefit with companies like ARTeSYN Biosolutions that are delivering cutting-edge technologies to the industry. And the elegant fluid control solutions ARTeSYN brings to the market help to simplify the route towards implementing single-use manufacturing.”
The systems will be fully industrialized following the standard for current good manufacturing practice (cGMP) manufacturing of biotech and biological products.
Pall Biotech, the biotech business sector of the corporation, will continue to expand its single-use solution portfolio with Allegro, its platform designed to integrate automated single-use technology solutions to the market for upstream and downstream processing through formulation and fill/finish.
According to the spokesperson, the partnership enables users to take advantage of automated systems for operations through the offerings such as, “The Allegro single-use chromatography solutions, which integrates ARTeSYN Biosolutions DRV values in a unique valve block assembly.”
“Whether a company is interested in gently starting to embrace single-use technology by integrating solutions into an existing stainless-steel line, or has fully embraced single-use by integrating whenever possible into the manufacturing line, these valves offer the right solution to start small and go big,” the spokesperson added.